Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
Blacks in the United States are less certain than whites about recommendations to prevent lung cancer and are more fearful of having symptoms evaluated — beliefs that may keep them from seeking timely treatment for the disease, researchers from Dana-Farber Cancer Institute reported at the American Society of Clinical Oncology's annual meeting in Chicago.
Blacks were also more likely to expect lung cancer to cause more symptoms prior to a diagnosis than were whites, said Christopher Lathan, MD, MPH, of Dana-Farber's Center for Outcomes and Policy Research and the study's lead author.
"These responses suggest that blacks may have a higher degree of fatalism about lung cancer," Lathan said, "and may contribute to black patients being diagnosed with more advanced stages of the disease because they have avoided going to the doctor or waited until symptoms appeared."
The researchers analyzed data from the 2005 HINTS survey in which 1,872 adults answered questions about lung cancer. While blacks and white patients shared many of the same beliefs, the survey data showed blacks were more likely to:
From these findings, Lathan and his colleagues concluded that "more attention should be paid to what people think about lung cancer, and we should think about ways to change misperceptions." The study's other authors are Cassandra A. Okechukwu of Dana-Farber, Bettina Drake, PhD, and Gary Bennett, PhD, of Dana-Farber and Harvard School of Public Health.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.